This “Yellow Fever - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Yellow Fever pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Yellow fever is an acute viral haemorrhagic disease transmitted by infected mosquitoes. The yellow fever virus is an arbovirus of the flavivirus genus and is transmitted by mosquitoes, belonging to the Aedes and Haemagogus species. Yellow fever appears with a sudden onset of fever, chills, headache, backache, nausea, and vomiting. The majority of people infected with yellow fever virus will either not have symptoms, or have mild symptoms and completely recover. Yellow fever is difficult to diagnose, especially during the early stages. More commonly it is diagnosed based on laboratory testing, a person's symptoms, and travel history.Good and early supportive treatment in hospitals improves survival rates. There is no medicine to treat or cure infection from yellow fever. Vaccination is the most important means of preventing yellow fever.
"Yellow Fever - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Yellow Fever pipeline landscape is provided which includes the disease overview and Yellow Fever treatment guidelines. The assessment part of the report embraces, in depth Yellow Fever commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Yellow Fever collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
This segment of the Yellow Fever report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Galidesivir: BioCryst Pharmaceuticals
Galidesivir (BCX4430) is a broad-spectrum antiviral in advanced development for the treatment of viruses that pose a threat to health and national security, including SARS-CoV-2 (the cause of COVID-19), Ebola, Marburg, Yellow Fever and Zika. BioCryst is developing Galidesivir in collaboration with U.S. government agencies and other institutions. Galidesivir is an adenosine nucleoside analog that acts to block viral RNA polymerase. BioCryst Pharmaceuticals completed phase I for Galidesivir.
TY014: Tychan Pte. Ltd.
TY014 is the first monoclonal antibody designed and engineered to treat yellow fever virus infections. TY014 is directed against the envelope (E) protein on the surface of the virus, and prevents viral replication by limiting viral fusion to host cells. Phase 1A of the TY014 study evaluated safety, tolerability and pharmacokinetics of this monoclonal antibody in healthy volunteers .
There are approx. 10+ key companies which are developing the therapies for Yellow Fever. The companies which have their Yellow Fever drug candidates in the most advanced stage, i.e. phase I include, BioCryst Pharmaceuticals.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Yellow Fever therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Yellow Fever drugs.
Geography Covered
- Global coverage
Yellow Fever Understanding
Yellow Fever: Overview
Yellow fever is an acute viral haemorrhagic disease transmitted by infected mosquitoes. The yellow fever virus is an arbovirus of the flavivirus genus and is transmitted by mosquitoes, belonging to the Aedes and Haemagogus species. Yellow fever appears with a sudden onset of fever, chills, headache, backache, nausea, and vomiting. The majority of people infected with yellow fever virus will either not have symptoms, or have mild symptoms and completely recover. Yellow fever is difficult to diagnose, especially during the early stages. More commonly it is diagnosed based on laboratory testing, a person's symptoms, and travel history.Good and early supportive treatment in hospitals improves survival rates. There is no medicine to treat or cure infection from yellow fever. Vaccination is the most important means of preventing yellow fever.
"Yellow Fever - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Yellow Fever pipeline landscape is provided which includes the disease overview and Yellow Fever treatment guidelines. The assessment part of the report embraces, in depth Yellow Fever commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Yellow Fever collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Yellow Fever R&D. The therapies under development are focused on novel approaches to treat/improve Yellow Fever.
Yellow Fever Emerging Drugs Chapters
This segment of the Yellow Fever report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Yellow Fever Emerging Drugs
Galidesivir: BioCryst Pharmaceuticals
Galidesivir (BCX4430) is a broad-spectrum antiviral in advanced development for the treatment of viruses that pose a threat to health and national security, including SARS-CoV-2 (the cause of COVID-19), Ebola, Marburg, Yellow Fever and Zika. BioCryst is developing Galidesivir in collaboration with U.S. government agencies and other institutions. Galidesivir is an adenosine nucleoside analog that acts to block viral RNA polymerase. BioCryst Pharmaceuticals completed phase I for Galidesivir.
TY014: Tychan Pte. Ltd.
TY014 is the first monoclonal antibody designed and engineered to treat yellow fever virus infections. TY014 is directed against the envelope (E) protein on the surface of the virus, and prevents viral replication by limiting viral fusion to host cells. Phase 1A of the TY014 study evaluated safety, tolerability and pharmacokinetics of this monoclonal antibody in healthy volunteers .
Yellow Fever: Therapeutic Assessment
This segment of the report provides insights about the different Yellow Fever drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Yellow Fever
There are approx. 10+ key companies which are developing the therapies for Yellow Fever. The companies which have their Yellow Fever drug candidates in the most advanced stage, i.e. phase I include, BioCryst Pharmaceuticals.
Phases
The report covers around 10+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Yellow Fever pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intramuscular
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Yellow Fever: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Yellow Fever therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Yellow Fever drugs.
Yellow Fever Report Insights
- Yellow Fever Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Yellow Fever Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Yellow Fever drugs?
- How many Yellow Fever drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Yellow Fever?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Yellow Fever therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Yellow Fever and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- BioCryst Pharmaceuticals
- Tychan Pte Ltd.
- CureVac AG
- Serum Institute of India Ltd
- Sanofi
- Emergex Vaccines
- Imutex Ltd
Key Products
- Galdesivir
- EMX001
- TV014
- Hydrovax-YFV
- Yellow fever Vaccine
Table of Contents
IntroductionExecutive Summary
Yellow Fever: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Yellow Fever - Analytical Perspective
In-depth Commercial Assessment
- Yellow Fever companies' collaborations, Licensing, Acquisition - Deal Value Trends
Yellow Fever Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
- Comparative Analysis
Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I)
- Comparative Analysis
Galidesivir: BioCryst Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
Preclinical Products
- Comparative Analysis
EMX-001: Emergex Vaccines
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Yellow Fever Key Companies
Yellow Fever Key Products
Yellow Fever - Unmet Needs
Yellow Fever - Market Drivers and Barriers
Yellow Fever - Future Perspectives and Conclusion
Yellow Fever Analyst Views
Yellow Fever Key Companies
AppendixList of Tables
Table 1 Total Products for Yellow Fever
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Yellow Fever
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- BioCryst Pharmaceuticals
- Tychan Pte Ltd.
- CureVac AG
- Serum Institute of India Ltd
- Sanofi
- Emergex Vaccines
- Imutex Ltd
